<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04054193</url>
  </required_header>
  <id_info>
    <org_study_id>0517-045</org_study_id>
    <secondary_id>2018-004844-43</secondary_id>
    <secondary_id>MK-0517-045</secondary_id>
    <nct_id>NCT04054193</nct_id>
  </id_info>
  <brief_title>Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)</brief_title>
  <official_title>A Phase 4, Open-label, Single Arm Study to Evaluate the Safety and Tolerability of a Three-day Fosaprepitant Regimen Administered for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants Receiving Emetogenic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of a 3-day intravenous
      (IV) fosaprepitant (MK-0517) regimen for the prevention of CINV in pediatric participants
      scheduled to receive emetogenic chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2019</start_date>
  <completion_date type="Anticipated">April 13, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 13, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced One or More Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 3.5 months</time_frame>
    <description>An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug. The percentage of participants who experience one or more AE(s) will be presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (AE)</measure>
    <time_frame>Up to approximately 3.5 months</time_frame>
    <description>An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug. The percentage of participants who discontinue study treatment due to an AE will be presented.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chemotherapy-induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Fosaprepitant Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 115 mg or an age-adjusted dose of intravenous (IV) fosaprepitant in combination with a 5-hydroxytryptamine 3 (5-HT3) antagonist on Day 1 of emetogenic chemotherapy. Following Day 1, participants will receive single-daily 80 mg or age-adjusted doses of IV fosaprepitant on Days 2 and 3 with or without a 5-HT3 antagonist. Participants may also receive dexamethasone at investigator's discretion based on the local standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosaprepitant</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>Fosaprepitant Regimen</arm_group_label>
    <other_name>EMEND for injection®</other_name>
    <other_name>MK-0517</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-HT3 antagonist</intervention_name>
    <description>Administered according to the product label or local standard of care</description>
    <arm_group_label>Fosaprepitant Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Administered according to the product label or local standard of care.</description>
    <arm_group_label>Fosaprepitant Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is receiving a moderately or highly emetogenic chemotherapy agent/regimen or a
             chemotherapy agent/regimen not previously tolerated due to vomiting

          -  Has a Lansky Play Performance score ≥60 (participants ≤16 years of age) or a Karnofsky
             score ≥60 (participants &gt;16 years of age)

          -  Has a pre-existing functional central venous catheter available for study treatment
             administration

          -  Is fosaprepitant naïve

          -  Has a predicted life expectancy ≥3 months

          -  A female participant is eligible to participate if she is not pregnant or
             breastfeeding, and at least one of the following conditions applies: is not a woman of
             childbearing potential (WOCBP) OR is a WOCBP and agrees to not be sexually active or
             use a highly effective contraceptive method for at least 28 days prior to receiving
             study treatment, during the treatment period, and for at least 30 days (or local
             standard of care if longer) after the last dose of study treatment (including the
             optional cycles)

          -  Has a negative highly sensitive pregnancy test (urine or serum as required by local
             regulations) prior to the start of fosaprepitant administration in a given cycle if a
             WOCBP

          -  Weighs at least 6 kilograms (kg)

        Exclusion Criteria:

          -  Will receive stem cell rescue therapy in conjunction with a study-related course of
             emetogenic chemotherapy or during the 14 days following administration of
             fosaprepitant

          -  Is currently a user of any recreational or illicit drugs or has current evidence of
             drug or alcohol abuse or dependence as determined by the investigator

          -  Is mentally incapacitated or has a significant emotional or psychiatric disorder that,
             in the opinion of the investigator, precludes study entry

          -  Is pregnant or breast feeding

          -  Is allergic to fosaprepitant, aprepitant, or prescribed 5-HT3 antagonist

          -  Has an active infection (eg, pneumonia), congestive heart failure, bradyarrhythmia,
             any uncontrolled disease (eg, diabetic ketoacidosis, gastrointestinal obstruction)
             except for malignancy, or has any illness which in the opinion of the investigator,
             might confound the results of the study or pose unwarranted risk in administering
             study treatment or concomitant therapy to the participant

          -  Is a WOCBP who has a positive pregnancy test at screening (Cycle 1) or on Day 1 of
             optional Cycles 2 or 3

          -  Has been started on systemic corticosteroid therapy within 72 hours prior to study
             treatment administration or is expected to receive a corticosteroid as part of the
             chemotherapy regimen. Exceptions apply

          -  Is taking excluded medications

          -  Has ever participated in a previous study of aprepitant or fosaprepitant or has taken
             a non-approved (investigational) drug within the last 4 weeks

          -  Has a known history of QT prolongation or is taking any medication that is known to
             lead to QT prolongation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Childrens Hospital ( Site 1101)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>602-933-5004</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern California Permanente Medical Group ( Site 1104)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>323-783-5307</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago ( Site 1106)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-227-4818</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota ( Site 1109)</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>612-813-5940</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital ( Site 1111)</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>901-595-8149</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Athens Childrens Hospital Aglaia Kyriakou ( Site 0101)</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+306973973179</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Athens - Aghia Sophia Childrens Hospital ( Site 0102)</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+306945709592</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Thessaloniki &quot;AHEPA&quot; ( Site 0103)</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 36</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+306944944777</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi OktatoKorhaz ( Site 0203)</name>
      <address>
        <city>Miskolc</city>
        <state>Borsod-Abauj-Zemplen</state>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36703113961</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem - Szent-Gyorgyi Albert Klinikai Kozpont ( Site 0201)</name>
      <address>
        <city>Szeged</city>
        <state>Csongrad</state>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36302487453</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heim Pal Orszagos Gyermekgyogyaszati Intezet ( Site 0202)</name>
      <address>
        <city>Budapest</city>
        <zip>1089</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36209463985</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>LSMUL Kauno Klinikos ( Site 0402)</name>
      <address>
        <city>Kaunas</city>
        <zip>50161</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+37037326033</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vaiku ligonine VsI VUL Santaros kliniku filialas ( Site 0401)</name>
      <address>
        <city>Vilnius</city>
        <zip>08406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+37069888347</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prinses Maxima Centrum ( Site 0501)</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31650006353</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Neoplasicas ( Site 1502)</name>
      <address>
        <city>Lima</city>
        <zip>15038</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5120165002706</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Anglo Americana ( Site 1501)</name>
      <address>
        <city>Lima</city>
        <zip>15073</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51998929868</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Delgado ( Site 1503)</name>
      <address>
        <city>Lima</city>
        <zip>15074</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51962709308</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instytut Matki i Dziecka ( Site 0601)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>01-211</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48223277205</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instytut Pomnik Centrum Zdrowia Dziecka ( Site 0602)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48228151774</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Regional Children Clinical Hospital ( Site 0705)</name>
      <address>
        <city>Chelyabinsk</city>
        <state>Chelyabinskaya Oblast'</state>
        <zip>454076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79517846624</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blokhin National Medical Oncology ( Site 0701)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74993242424</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dmitry Rogachev National Research Center ( Site 0704)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79161666692</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of specialized types medical care-Oncology ( Site 0706)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79219316905</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust ( Site 1002)</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441133922159</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alder Hey Childrens NHS Foundation Trust Hospital ( Site 1003)</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441512525294</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital ( Site 1005)</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441617010914</phone>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Serotonin 5-HT3 Receptor Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

